AJANTPHARM

Ajanta Pharma Financial Results

₹3,575.70+0.06%
Market cap
₹44,673 crore
P/E
39.4
P/B
9.87
ROE
25.4%
Dividend yield
0.89%

For the year ended Mar 2019, Ajanta Pharma reported revenue of ₹2,055 crore and net profit of ₹387 crore, against ₹2,588 crore and ₹468 crore a year earlier.

Ajanta Pharma annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Ajanta Pharma annual profit and loss (₹ crore)
ItemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue2,0552,5882,8903,3413,7084,1624,5885,4075,731
Expenses1,4891,9051,8912,4122,8972,9813,3153,9084,038
Operating profit5666839999298111,1811,2731,5001,693
Operating margin %28%26%35%28%22%28%28%28%30%
Other income21882611671758167-9
Interest11281067211614
Depreciation7296116125131135144173176
Profit before tax5146649009097451,1141,1891,3781,493
Tax %25%30%27%22%21%27%23%23%24%
Net profit3874686547135888169201,0561,135
EPS (₹)30.2936.9251.620.0046.4164.8273.6884.5290.84
Dividend payout %—————————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Ajanta Pharma financial results — frequently asked questions

What is Ajanta Pharma's annual revenue and net profit?

For the financial year ended Mar 2019, Ajanta Pharma's revenue was ₹2,055 crore and net profit ₹387 crore; net profit fell 17.31% from ₹468 crore in Mar 2020.

How fast has Ajanta Pharma grown over three years?

From Mar 2022 to Mar 2019, Ajanta Pharma's revenue grew at a compound annual rate of -15.0% and net profit at -18.4%. Past growth does not indicate future results.

What is the EPS of Ajanta Pharma?

Annual EPS for Mar 2019 was ₹30.29.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Ajanta Pharma With ATS

Track AJANTPHARM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.